Search: id:"swepub:oai:gup.ub.gu.se/185476" >
Immunotherapeutic s...
Immunotherapeutic strategies for relapse control in acute myeloid leukemia
-
- Martner, Anna, 1979 (author)
- Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
-
- Bergh Thorén, Fredrik, 1976 (author)
- Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
-
- Aurelius, Johan, 1980 (author)
- Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
-
show more...
-
- Hellstrand, Kristoffer, 1956 (author)
- Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2013
- 2013
- English.
-
In: Blood Reviews. - : Elsevier BV. - 0268-960X. ; 27:5, s. 209-216
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Despite that the initial phases of chemotherapy induce disappearance of leukemic cells in many patients with acute myeloid leukemia (AML), the prevention of life-threatening relapses in the post-remission phase remains a significant clinical challenge. Allogeneic bone marrow transplantation, which is available for a minority of patients, efficiently prevents recurrences of leukemia by inducing immune-mediated elimination of leukemic cells, and over the past decades, numerous immunotherapeutic protocols have been developed aiming to mimic the graft-versus-leukemia reaction for the prevention of relapse. Here we review past and present strategies for relapse control with focus on overcoming leukemia-related immunosuppression in AML. We envisage future treatment protocols, in which systemic immune activators, such as vaccines, dendritic cell-based therapies, engineered variants of IL-2, or IL-15, are combined with agents that counter immunosuppression mediated by, e.g., the PD/PDL interaction, CTLA-4, CD200, reactive oxygen species, IDO expression, CXCR4, or the KIR/class I interaction, based on characteristics of the prevailing malignant clone. This combinatorial approach may pave the way for individualized immunotherapy in AML.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Acute myeloid leukemia
- Maintenance therapy
- Leukemia-related immunosuppression
- REGULATORY T-CELLS
- ACUTE MYELOGENOUS LEUKEMIA
- BONE-MARROW-TRANSPLANTATION
- POST-CONSOLIDATION IMMUNOTHERAPY
- REMISSION
- MAINTENANCE THERAPY
- ACUTE PROMYELOCYTIC LEUKEMIA
- KIR LIGAND
- INCOMPATIBILITY
- HUMORAL IMMUNE-RESPONSES
- 1ST COMPLETE REMISSION
- LOW-DOSE INTERLEUKIN-2
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database